New Executive Director to lead The George Institute, China

The George Institute for Global Health, China (TGI China) today announced that world renowned clinician-scientist Professor Craig Anderson will be the new Executive Director for TGI China, taking over from Professor Zhi-Jie Zheng.

Dr. Anderson is currently Professor of Stroke Medicine and Clinical Neuroscience in the Sydney Medical School at the University of Sydney, and a Senior Principal Research Fellow of the National Health and Medical Research Council.  He recently stepped down as Head of the Neurology Department at Royal Prince Alfred Hospital, a premier teaching hospital in Sydney, to move to Beijing and support TGI China’s academic leadership.  

“China is facing enormous challenges from non-communicable diseases such as cardiovascular disease, and chronic disability, and with its research, TGI China is well positioned to help China reduce the NCD burden and improve the lives of millions of Chinese people. I have been fortunate to have been involved in China’s medical development over many decades and my recent increased time with TGI China has highlighted for me the exciting opportunities for further research opportunities and partnerships,” said Dr Anderson.  “I want to thank Professor Zheng for his work on behalf of The George and for his many contributions.” 

Professor Zheng, who joined TGI last year, decided that there were too many demands on his time with continuing additional roles as University Distinguished Professor of Public Health and Medicine, as well as Dean of the School of Public Health at Shanghai Jiao Tong University.

Professor Anderson has received several Research Excellence awards, including from Royal Prince Alfred Research, the University of Sydney, and the Stroke Society of Australasia (SSA). He is a member of several specialist societies, an Editor for the Cochrane Stroke Group, and former President of SSA and the Asia Pacific Stroke Organisation (APSO).

He continues to lead several major international studies on stroke, hypertension, and cardiovascular medicine for both the Institute as well as George Clinical, which is part of George Health Enterprises, a commercial branch of the Institute. For instance, he is Principal Investigator of the INTERACT study, a large global trial with significant involvement of China, that indicated that early intensive blood pressure control improves recovery from hemorrhagic stroke which is very common in Asian people. Further, he recently announced results of the ENCHANTED study that involved over 3000 patients with acute ischemic stroke, two thirds of whom were recruited in Asia, showing a lower dose of the clot-busting drug alteplase improves safety of the treatment. He has published widely on the clinical and epidemiological aspects of stroke, cardiovascular disease and aged care, with over 300 original research papers and many presentations and international conferences.